Background To gain a global perspective on short-acting β2-agonist (SABA) prescriptions
and associated asthma-related clinical outcomes in patients with asthma, we assessed …

Objective Short-acting β2-agonist (SABA) over-reliance is associated with poor asthma
outcomes. As part of the SABA Use IN Asthma (SABINA) III study, we assessed SABA …

Background Overuse of short-acting β 2-agonists (SABA) may indicate poor asthma control
and adverse health outcomes. Contemporary population-based data on use, risk factors and …

Introduction Patients with asthma typically increase short-acting β 2-agonists (SABA) use
with worsening symptoms. Excessive SABA use may lead to a higher risk of adverse …

Background Expert national/global asthma management recommendations raise the issue
whether a safe threshold of short-acting beta-2 agonist (SABA) use without concomitant …

Background Inappropriate use of short-acting beta-agonists (SABA) has been associated
with increased morbidity and mortality in asthma. However, the extent and pattern of SABA …

As SABA overuse is associated with exacerbations and mortality, GINA no longer
recommends SABA only as a preferred reliever in asthma. A consistent pattern of high SABA …

Introduction Globally, individuals with asthma tend to overrely on short-acting β 2-agonists
(SABAs) and underuse inhaled corticosteroids, thereby undertreating the underlying …

Despite the availability of effective asthma treatments, some patients are poorly controlled
because of overreliance on short-acting β 2-agonists (SABAs) and underuse of inhaled …

BACKGROUND: Short-acting β-agonist (SABA) use is well established in predicting asthma
events in adults. However, this predictive ability has yet to be established in a pediatric …